Short-term treatment of pertussis with azithromycin in infants and young children

Eur J Clin Microbiol Infect Dis. 1999 Apr;18(4):296-8. doi: 10.1007/s100960050281.

Abstract

A prospective, open, noncomparative study was conducted to assess the efficacy and safety of azithromycin given once daily for 3 or 5 days to eradicate Bordetella pertussis from the upper respiratory tract of infants and young children. Seventeen children received azithromycin in a dose of 10 mg/kg on day 1 followed by 5 mg/kg once daily for four consecutive days, and 20 were given 10 mg/kg once daily for 3 days. Seven days after the initiation of therapy, 33 of 35 (94.3%) patients had negative cultures for Bordetella pertussis. On day 14, cultures from all 34 evaluable patients were negative. These findings suggest that a controlled, comparative study of erythromycin versus short-term administration of azithromycin is justified.

Publication types

  • Clinical Trial

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Azithromycin / therapeutic use*
  • Bordetella pertussis / isolation & purification
  • Culture Media
  • Female
  • Humans
  • Infant
  • Male
  • Prospective Studies
  • Treatment Outcome
  • Whooping Cough / drug therapy*
  • Whooping Cough / microbiology

Substances

  • Anti-Bacterial Agents
  • Culture Media
  • Azithromycin